All In Biotech

Drug Trial Radar · NCT03061721

Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis

A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis

Last checked: Nov 20, 2026Latest source record: Oct 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

106

Actual

Start

Apr 6, 2017

Primary completion

Aug 22, 2019

Study completion Aug 22, 2019

Sponsor

Lead sponsor
Zydus Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Feb 23, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled study in up to 104 patients with a diagnosis of Non-alcoholic fatty Liver disease (NAFLD) and/or Non-alcoholic steatohepatitis (NASH). The study will be conducted over a period of up to 22 weeks and will include an optional Prescreening, Screening (Days -35 to -7) Phase, a 16-week Treatment Phase following randomization on Day 1. Patients will be randomly assigned in a ratio of 1:1:1:1 to receive Saroglitazar Magnesium 1mg or 2 mg or 4 mg or matching placebo once daily in the morning before breakfast for 16 Weeks. The primary endpoint of the study is percentage change from baseline in serum Alanine transaminase (ALT) levels at Week 16 in the Saroglitazar Magnesium groups as compared to the placebo group.

Conditions

  • Non-Alcoholic Fatty Liver Disease
  • Nonalcoholic Steatohepatitis

Interventions

  • Saroglitazar magnesium 1 mgDrug

    Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.

  • Saroglitazar magnesium 2 mgDrug

    Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.

  • Saroglitazar magnesium 4 mgDrug

    Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.

  • PlacebosDrug

    Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change From Baseline in Serum Alanine Aminotransferase (ALT) Levels at Week 16Time frame: Baseline and Week 16

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Precision Research

    Chula Vista, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Catalina Research Institute

    Montclair, California

  • California liver research institute

    Pasadena, California

  • Precision Research

    San Diego, California

  • University of Florida

    Gainesville, Florida

  • Schiff Center for Liver Diseases/University of Miami

    Miami, Florida

  • Avail Clinical Research

    Orange City, Florida

  • Indiana University

    Indianapolis, Indiana

  • Mercy Medical Center

    Baltimore, Maryland

  • University of Michigan

    Ann Arbor, Michigan

  • Awasty Research Network, LLC

    Marion, Ohio

  • Einstein Medical Center

    Philadelphia, Pennsylvania

  • Gastro One

    Germantown, Tennessee

  • AIG Research

    Hermitage, Tennessee

  • Liver Consultants

    Dallas, Texas

  • The Liver Institute

    San Antonio, Texas

  • Swedish Medical Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.